| MFS | GBS-OP(+) | |||||
| Group 1 | Group 2 | Group 3 | Group 1 | Group 2 | Group 3 | |
| (n = 32) | (n = 26) | (n = 4) | (n = 9) | (n = 15) | (n = 10) | |
| GQ1b | 32 (100%) | 23 (89%) | 4 (100%) | 9 (100%) | 12 (80%) | 9 (90%) |
| GT1a | 27 (84%) | 13 (50%) | 3 (75%) | 6 (67%) | 12 (80%) | 9 (90%) |
| To GSCs containing GQ1b or GT1a: | ||||||
| GQ1b/GM1 | 0 | 13 (50%) | 0 | 0 | 6 (40%) | 0 |
| GQ1b/GD1b | 0 | 4 (15%) | 0 | 0 | 8 (53%) | 0 |
| GT1a/GM1 | 0 | 21 (81%) | 0 | 0 | 13 (87%) | 0 |
| GT1a/GD1b | 0 | 20 (77%) | 0 | 0 | 14 (93%) | 0 |
| GT1a/GM2 | 0 | 5 (19%) | 0 | 0 | 1 (6.7%) | 0 |
| GQ1b/GM2 | 0 | 1 (4.0%) | 0 | 0 | 1 (6.7%) | 0 |
| GQ1b/GD1a | 0 | 0 | 2 (50%) | 0 | 2 (13%) | 4 (40%) |
| GQ1b/GT1b | 0 | 0 | 3 (75%) | 0 | 3 (20%) | 7 (70%) |
| GT1a/GD1a | 0 | 0 | 2 (50%) | 0 | 4 (27%) | 6 (60%) |
| GT1a/GT1b | 0 | 0 | 3 (75%) | 0 | 1 (6.7%) | 6 (60%) |
| GQ1b/GT1a | 0 | 0 | 1 (25%) | 0 | 0 | 3 (30%) |
| Others | None | None | None | None | None | None |
Thirty MFS patients and 25 GBS-OP(+) patients had anti-GSC antibodies. Of these, 26 MFS patients were categorised in group 2 and only four in group 3. For 25 GBS-OP(+) patients, these numbers were 15 (in group 2) and 10 (in group 3).
GBS Group 2 and GBS-OP(−) patients had IgG antibodies to other GSCs: two (13%) patients in GBS Group 2 had antibodies to GM1/GD1a, 5 (33%) to GM1/GT1b, 1 (7%) to GD1a/GD1b and 2 (13%) to GD1b/GT1b. Two (4%) patients in GBS-OP(−) had antibodies to GM1/GD1a, 2 (4%) to GM1/GT1b and 1 (2%) to GD1a/GD1b.
GBS-OP(+), Guillain–Barré syndrome syndrome with ophthalmoplegia; GBS-OP(−), Guillain–Barré syndrome without ophthalmoplegia; GSCs, ganglioside complexes; IgG, immunoglobulin G; MFS, Miller Fisher syndrome.